Graft

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to register today!

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Otto, C.
Right arrow Articles by Ulrichs, K.
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Graft, Vol. 5, No. 3, 132-134 (2002)
DOI: 10.1177/1522162802005003003
© 2002 SAGE Publications

Immunomodulation with MHC Class II Peptides after Small Bowel Transplantation: Influence on Rejection and Outcome

Christoph Otto

Wolfgang Timmermann

Anne Cathrin Rohde

Ana Maria Waaga

Martin Gasser

Detlef Meyer

Heinz-Jochen Gassel

Arnulf Thiede

Karin Ulrichs

T-cell recognition of allogeneic major histocompatibility complex (MHC) peptides presented by self-MHC molecules initiates allograft rejection. Under certain conditions, synthetic MHC peptides are able to inhibit the allogeneic T-cell response. The present study was designed to evaluate the effect of MHC class II peptides RT1.D2 and RT1.B2, corresponding to the hypervariable domain of Wistar Furth (WF) rat, combined with low-dose cyclosporine A (CsA) in experimental small bowel transplantation. In the rat strain combination WF-to-LEW, preoperatively administered RT1.B2 peptide (50 g per rat) (but not RT1.D2 peptide) showed immunoinhibitory effects were seen and allograft survival was prolonged to a mean of 106 ±24.3 days in 43% of the Lewis graft (LEW) recipients. The graft survival after CsA application alone was limited to 49.9 ±8.3 days. In combination with peptide RT1.D2, the survival time was 47.1 ±3.8 days. The authors have evidence that the combination of CsA with peptide RT1.B2 induces specific unresponsive-ness in alloreactive T-cells. These promising results indicate that it is possible to suppress the T-cell-dependent alloresponse by the indirectly presented MHC class II peptide RT1.B2 in combination with low-dose CsA, to prolong small bowel allograft survival.

Key Words: allorecognition • MHC • peptides • T cells • Cyclosporin A


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?